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OBJECTIVES This study evaluated both short- and long-term outcomes of diabetic patients who underwent
repeat coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention
(PCI) after initial CABG.
BACKGROUND Although diabetic patients who have multivessel coronary disease and require initial
revascularization may benefit from CABG as compared with PCI, the uncertainty concerning
the choice of revascularization may be greater for diabetic patients who have had previous
CABG.
METHODS Data were obtained over 15 years for diabetic patients undergoing PCI procedures or repeat
CABG after previous coronary surgery. Baseline characteristics were compared between
groups, and in-hospital, 5-year, and 10-year mortality rates were calculated. Multivariate
correlates of in-hospital and long-term mortality were determined.
RESULTS Both PCI (n  1,123) and CABG (n  598) patients were similar in age, gender, years of
diabetes, and insulin dependence, but they varied in presence of hypertension, prior
myocardial infarction, angina severity, heart failure, ejection fraction, and left main disease.
In-hospital mortality was greater for CABG, but differences in long-term mortality were not
significant (10 year mortality, 68% PCI vs. 74% CABG, p  0.14). Multivariate correlates of
long-term mortality were older age, hypertension, low ejection fraction, and an interaction
between heart failure and choice of PCI. The PCI itself did not correlate with mortality.
CONCLUSIONS The increased initial risk of redo CABG in diabetic patients and the comparable high
long-term mortality regardless of type of intervention suggest that, except for patients with
severe heart failure, PCI be strongly considered in all patients for whom there is a
percutaneous alternative. (J Am Coll Cardiol 2002;40:1968–75) © 2002 by the American
College of Cardiology Foundation
As the care of patients undergoing coronary artery bypass
graft surgery (CABG) improves, patients expect to survive
for many years after their surgery. This longevity, however,
increases the likelihood of repeat coronary intervention
secondary to the development of atherosclerotic disease in
these patients’ bypass grafts or progression of disease in their
native vessels. This problem is magnified in importance in
diabetic patients, who are more likely to experience long-
term problems, including failure of their bypass grafts, after
CABG (1).
Patients who present in need of revascularization after
previous bypass surgery have two available options—a repeat
coronary surgery or percutaneous coronary intervention
(PCI). In many cases, each of these options is viable, and it
is not clear which is preferable for a given patient. In a
meta-analysis of the large trials conducted to evaluate initial
CABG versus PCI, no significant mortality benefit was
observed for one procedure compared to the other (2).
Instead, the CABG patients required fewer repeat proce-
dures at the expense of greater initial cost. However, in the
Bypass Angioplasty Revascularization Investigation (BARI)
trial, the 19% of patients who were diabetic had 81%
five-year survival rates when treated with CABG but only
66% five-year survival when treated with balloon angio-
plasty (3,4). Similar results were also apparent in recent data
from the Coronary Angioplasty versus Bypass Revascular-
ization Investigation (CABRI) study, which showed higher
mortality for diabetic patients, but not nondiabetic patients,
when treated with PCI as opposed to CABG (5). It is
notable, however, that whereas this effect has been shown
for the diabetic subset in these randomized trials, the patient
populations only included first-time CABG patients with
multivessel disease.
In another large trial, at eight-year follow-up, there is a
trend—although not statistically significant—toward de-
creased long-term mortality in diabetic patients treated with
CABG as opposed to PCI (6). Furthermore, the negative
interaction between diabetes and choice of PCI as opposed
to CABG has been demonstrated, although inconsistently,
in observational studies from large databases (1,7) and
appears in analysis of the BARI registry (8). A question that
remains beyond these studies, however, is whether previous
bypass surgery affects the relative risk profile for diabetic
patients undergoing revascularization. Can a second CABG
provide the same marginal benefit to diabetic patients?
With the advent of coronary stenting, technical success
rates and long-term survival have improved in all patients
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undergoing PCI after prior CABG (9,10). Furthermore,
evidence exists that among all patients with previous
CABG, there is no overall mortality difference between
patients treated with different revascularization methods
(11). Thus, it may be appropriate to look at clinical and
angiographic criteria specific to a given patient in an effort to
choose PCI or CABG. In this setting, the present study
evaluates both the in-hospital and long-term outcomes of
diabetic patients who underwent PCI or redo CABG after
initial CABG.
METHODS
Patient population, procedures, and variables. The study
population was drawn from all patients presenting to Emory
University hospitals from 1985 to 1999. Patients were
included if they had a diagnosis of diabetes and previously
had undergone CABG. Diabetic patients were defined as
those who were receiving active treatment for diabetes
mellitus with either insulin or an oral hypoglycemic agent at
the time of intervention. Diet-controlled diabetic patients
were only included in the study if documentation showed a
fasting blood glucose level of 140 mg/dl or a random
blood glucose of 200 mg/dl available during hospitaliza-
tion. Patients underwent revascularization procedures (ei-
ther PCI or CABG) in the setting of stable or unstable
angina or after several days of stabilization following acute
myocardial infarction (MI). Procedures performed acutely
for MI were not included in the analysis. All angioplasty
procedures were performed by standard techniques that
have been previously described (12). Procedures performed
included balloon angioplasty, coronary stent implantation,
directional atherectomy, and evaluation of other new pro-
cedures. Patients who had reoperative CABG had surgery
performed with standard surgical techniques (13).
Variables defined by patient history included age, gender,
number of years of diagnosed diabetes, duration of time
since first CABG, insulin dependence, hypertension, prior
MI, heart failure, severity of angina, ejection fraction, and
number of vessels diseased. Angina was defined according to
the Canadian Cardiovascular Society Classification (14),
and congestive heart failure (CHF) by New York Heart
Association criteria (15). Single-vessel disease was defined
as 50% diameter luminal narrowing of the left anterior
descending artery (LAD), left circumflex artery (LCX),
right coronary artery, or a major branch of these arteries.
Two-vessel disease required the presence of at least 50%
narrowing in two of the three major epicardial vessel
systems, and three-vessel disease involved all three arteries
(or LAD and proximal LCX disease in left-dominant
systems).
Defined complications were the development of a new
Q-wave MI postprocedure or a stroke, defined as a neuro-
logic event with persisting changes in neurologic function
after the procedure.
Data collection. All baseline data as well as procedural
results were recorded prospectively on standardized forms
and entered into a computerized database. Determination of
angiographic success was based on quantitative angio-
graphic calculation performed by angiographers involved in
the procedure, but other than the primary operator.
Follow-up information was obtained directly from patients,
from their referring physicians, by telephone or letter
follow-up, and from data assessed at each subsequent
hospital admission. Key elements of information obtained
in follow-up related to patient survival, cause of death
(cardiac or noncardiac), recurrent hospitalization, the occur-
rence of MI, and any need for repeat revascularization.
Statistical analysis. Continuous data were expressed as
mean  SD and categorical data as proportions. Continu-
ous data were compared by unpaired t test and categorical
data by chi-square test. Missing data were filled in according
to the method of Harrell (16). All variables were considered
potential covariates of in-hospital and long-term mortality.
Correlates of in-hospital outcome were assessed by logistic
regression, whereas correlates of long-term outcome were
analyzed by the Cox proportional hazards survival model
(17). Multivariate correlates of in-hospital and long-term
mortality were expressed as odds ratio (OR) and hazard
ratios (HRs), respectively. Potential nonlinear effects of each
of the continuous predictor variables were checked using
restricted cubic splines. Interaction terms were assessed.
The discrimination of the models was assessed by the c (or
concordance) index, which is the fraction of pairs of
patients, one with a given end point, correctly identified.
The models were validated and calibrated according to the
method of Harrell (16), and overall survival (cardiac plus
noncardiac) was determined and expressed by the Kaplan-
Meier method (18).
RESULTS
Baseline characteristics of the 1,721 diabetic patients who
underwent repeat revascularization are included in Table 1.
Follow-up was obtained for 98% of the patients. Of note,
the 1,123 patients who underwent PCI and the 598 patients
Abbreviations and Acronyms
BARI  Bypass Angioplasty Revascularization
Investigation
CABG  coronary artery bypass graft surgery
CABRI  Coronary Angioplasty versus Bypass
Revascularization Investigation
CHF  congestive heart failure
CI  confidence interval
HR  hazard ratio
IMA  internal mammary artery
LAD  left anterior descending artery
LCX  left circumflex artery
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous coronary intervention
SVG  saphenous vein graft
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who had redo CABG were similar in age, gender, years of
diabetes, and insulin dependence. However, hypertension
and prior MI were significantly more prevalent in the subset
undergoing CABG. A majority of all patients had class III
to IV angina, but this finding was noted more frequently in
patients who underwent PCI. Heart failure, while noted in
a minority of patients, was more common among those
undergoing CABG (24.3% vs. 15.6%). It is also notable that
the vast majority of patients in both groups had multivessel
disease, with more of the PCI patients having two- and
three-vessel disease and a higher proportion of CABG
patients with left main disease. Ejection fraction was rela-
tively well preserved within both groups, but higher in the
PCI patients.
Outcomes are detailed in Table 2. Reflecting the time
during which these patients were treated, only 25.02% of
the PCI patients underwent coronary stenting. Also,
43.19% of the percutaneous procedures involved a saphe-
nous vein graft (SVG) site. Notable regarding the CABG
patients is that 48.5% of these patients had an internal
mammary artery (IMA) graft placed in the setting of redo
CABG. In-hospital mortality was significantly higher with
redo CABG, and Q-wave MI was more frequent in the
CABG group. Stroke was a significantly more frequent
complication (4.68% vs. 0.09%, p  0.0001) in patients
undergoing CABG. Both postprocedure hospital stay and
cost of initial hospitalization were significantly higher in the
CABG group. Figure 1 demonstrates long-term survival for
the two groups of patients. Despite the higher in-hospital
mortality associated with redo CABG in these patients, the
long-term differences are much smaller. Mortality differ-
ences were not significant between the two groups at either
5 years (38% PCI vs. 39% CABG) or 10 years (68% PCI vs.
74% CABG, p  0.14). An additional revascularization
with CABG (Fig. 2) was more common in patients initially
treated with PCI (p  0.0001).
Multivariate analysis was performed to evaluate patient
survival in each group in light of underlying differences
between the patient populations. Multivariate correlates of
in-hospital mortality are included in Table 3, and correlates
of long-term mortality are in Table 4. The strongest
correlate of in-hospital mortality was coronary surgery, with
an OR of 6.51 (95% confidence interval [CI] 3.75 to 11.28)
(Table 3). However, year of the revascularization procedure
(OR 0.92 per 1-year increase, 95% CI 0.86 to 0.97), age
(OR 1.51 per 10-year increase in age, 95% CI 1.13 to 2.50),
patient gender (male gender OR 0.42, 95% CI 0.25 to
0.68), and lower ejection fraction (OR 0.71 per 10%
increase in ejection fraction, 95% CI 0.59 to 0.86), also
correlated with in-hospital mortality. The variables that
Table 1. Characteristics of Diabetic Patients Undergoing Intervention After Prior CABG
Total Patients PCI CABG p Value
(n  1,721) (n  1,123) (n  598) (PCI vs. CABG)
Age 64  9 64  9 64  9 0.95
Female gender 27% 27% 26% 0.62
Years of diabetes 10.6  9 (n  1,026) 10.8  9.2 (n  758) 10.3  8.3 (n  268) 0.52
Years from 1st CABG 7.17  4.45 (n  1,510) 6.64  4.26 (n  1,003) 8.21  4.65 (n  507)  0.0001
Insulin dependence 40% 38% 42% 0.19
Hypertension 72% 69% 76% 0.006
Prior MI 60% 56% 67% 0.0001
Class III to IV angina 77% 79% 72% 0.0007
Heart failure 18.2% 15.6% 24.3% 0.0001
1-Vessel disease 6.4% 6.6% 5.8% 0.66
2-Vessel disease 19.8% 21.9% 14.3% 0.001
3-Vessel disease 69.2% 71.5% 62.8% 0.001
Left main disease 4.6% 0% 17.1%  0.001
Ejection fraction 48  13 (n  1,324) 49  13 (n  996) 47  14 (n  328) 0.02
CABG  coronary artery bypass graft; MI  myocardial infarction; PCI  percutaneous coronary intervention.
Table 2. Outcomes After CABG vs. PCI
Total Patients PCI CABG p Value
(n  1,721) (n  1,123) (n  598) (PCI vs. CABG)
Coronary stent 25.02%
IMA graft 48.5%
SVG PCI 43.19%
Hospital mortality 4.95% 1.61% 11.2%  0.0001
Q-wave MI 1.92% 1.25% 3.18% 0.01
Stroke 1.69% 0.09% 4.68%  0.0001
Postprocedure hospital stay (days) 5.76  9.42 3.01  4.84 10.91  13.06  0.0001
Hospital cost ($) 13,266  14,295 8,537  7,537 23,240  19,218  0.0001
(n  1,508) (n  1023) (n  485)
CABG  coronary artery bypass graft; IMA  internal mammary artery; MI  myocardial infarction; PCI  percutaneous
coronary intervention; SVG  saphenous vein graft.
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correlated with long-term mortality (Table 4) also included
age (HR 1.56 per 10 years, 95% CI 1.42 to 1.71), gender
(HR for males 0.83, 95% CI 0.69 to 1.00), and ejection
fraction (per 10% increase in ejection fraction, HR 0.77,
95% CI 0.72 to 0.83), along with hypertension (HR 1.30,
95% CI 1.09 to 1.56).
Class III to IV CHF was a significant correlate of
long-term mortality for patients managed with PCI (HR
1.54, 95% CI 1.25 to 1.89) but not for patients treated with
CABG (HR 1.19, 95% CI 0.97 to 1.45) (Table 4). Thus,
the only significant interaction in the long-term mortality
model was between type of revascularization and CHF.
Figure 3 demonstrates this strong trend, consistent with
multivariate analysis, for poorer survival in CHF patients
treated with PCI, which is not noted in the patients without
CHF. Of note, CHF was a strong predictor of mortality
after either revascularization strategy (p  0.03 for CABG
and p  0.0001 for PCI). A final analysis demonstrated
that, for patients undergoing CABG, those treated with an
internal mammary graft were at lower long-term risk (HR
0.77, 95% CI 0.59 to 1.00, p 0.048). Choice of PCI itself
was not a long-term correlate of mortality, either overall
(Table 4) or if PCI were compared to the CABG subgroup
receiving an IMA graft (HR for CABG compared to PCI
0.88, 95% CI 0.69 to 1.14, p  0.37).
DISCUSSION
This study analyzes short- and long-term mortality for
diabetic patients who underwent repeat coronary interven-
tion following bypass surgery. A first observation is that
these patients, with long-term mortality of approximately
70% at 10 years (no matter which method of revasculariza-
tion was chosen), are some of the sickest ischemic heart
disease patients encountered in cardiology practice. Addi-
tionally, reflecting operative and early postoperative mortal-
ity, repeat revascularization with CABG is associated with
significant early mortality excess. The variables that corre-
late with long-term mortality—most notably older age,
hypertension, and depressed ejection fraction—relate to the
underlying disease process in these patients. Multivariate
analysis does not reveal choice of revascularization to cor-
relate with long-term mortality. The only significant inter-
action was between patients with advanced (class III to IV)
heart failure and the choice of PCI.
This trend toward worse outcomes with PCI and CHF
also manifests in the long-term survival curves for CHF
Figure 1. Kaplan-Meier survival curve for revascularization with percutaneous coronary intervention (PCI) versus redo coronary artery bypass graft surgery
(CABG).
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patients, raising the possibility that these particularly sick
patients may not do as well with PCI. However, except for
this small subset of patients with severe CHF, the data on
long-term mortality provide no support for one method of
revascularization over the other. In fact, given the demon-
stration of a profound initial risk for redo CABG in these
diabetic patients (over 11% in-hospital mortality in our
cohort), this study suggests consideration of PCI for those
patients in whom there is a percutaneous alternative.
There are limitations to the generalizability of these data.
Medical therapy, PCI, and CABG have changed signifi-
cantly over the years of this analysis. Even the definition of
diabetes has changed, and the currently accepted definition
of a fasting glucose value 126 mg/dl, adopted by the
American Diabetes Association in 1997 and the World
Health Organization in 1999 (19), considers as diabetic
some patients not included in this analysis. Medical therapy,
including the aggressive use of statin therapy and
angiotensin-converting enzyme inhibitors, has also evolved
since the mid-1980s. Furthermore, newer interventional
techniques, most notably stenting, may allow diabetic pa-
tients to have better outcomes than previously available with
percutaneous intervention (20,21). Reflecting the changing
practice patterns over the course of 15 years, only 25% of the
patients undergoing PCI in this study had the placement of
intracoronary stents, and the use of stents is even more
important in a population of patients with SVGs, given the
significant benefit that has been demonstrated for stenting
SVGs (9). At the same time, cardiac surgical techniques
continue to evolve, including the more common use of off-
pump CABG with acceptable mortality (22). In combination
with the natural evolution of cardiac anesthesia (23) and the
use of multiple arterial grafts (24,25), evidence shows that, over
the course of time, mortality outcomes with CABG have been
improving. The result of these improvements in both PCI and
CABG is that physicians may often have more confidence
sending their patients for either of these interventions.
Table 3. Multivariate Correlates of In-Hospital Mortality
(C Index 0.807, Validated 0.801)
Odds
Ratio 95% CI p Value
Year of procedure (increase of 1) 0.92 0.86–0.97 0.0036
Age (per 10 years) 1.51 1.13–2.00 0.0046
Hypertension 1.75 0.99–3.11 0.056
Male gender 0.42 0.25–0.68 0.0005
Ejection fraction (10% increase) 0.71 0.59–0.86 0.0003
CABG 6.51 3.75–11.28  0.0001
CABG  coronary artery bypass graft surgery; CI  confidence interval.
Figure 2. Curve demonstrating repeat coronary artery bypass graft surgery (CABG) after index procedure in diabetic patients treated with a second CABG
or percutaneous coronary intervention (PCI) after first CABG.
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However, these changes in medical and surgical outcomes
bias decision making for many diabetic patients toward
PCI. For example, the value of intracoronary stents in a
diabetic population has seemed to increase greatly with the
addition of the glycoprotein IIb/IIIa inhibitors (20), which
would have been used in even fewer than the 25% of
patients receiving stents in our analysis. Similarly, the use of
vascular brachytherapy to treat in-stent restenosis has
proven to be quite effective in the diabetic population, and
new strategies for distal protection make SVG intervention
safer in both diabetic and nondiabetic patients. It is hoped
that greater numbers of these diabetic patients will ulti-
mately be able to benefit from percutaneous intervention
after initial coronary surgery, with the potential caveats that
patients who can receive an arterial conduit or patients with
severe CHF may be more likely to obtain a relative benefit
from another coronary surgery.
Other potential limitations of these data relate to their
derivation from a large database. However, excellent
follow-up and the comprehensive nature of the database
give credibility to the results. Although there may be
limitations to the letter and telephone follow-up techniques
required to maintain the database, end points of mortality or
repeat revascularization are readily assessed by these means.
Nonetheless, the analysis still is dependent on observational,
nonrandomized data. It remains possible that selection bias
may have led to certain less sick patients undergoing PCI
(with surgeons only being referred patients in whom there
were no discrete lesions easily amenable to percutaneous
therapy), but it is also likely that there was a group of
patients selected for PCI who were too sick for CABG.
Although multivariate analysis did not find choice of revas-
cularization to be correlated with long-term survival in these
patients, multivariate analysis cannot account for unmea-
sured confounders affecting selection. Undoubtedly, certain
patients in both the PCI and redo CABG groups could not
have effectively been treated with the other method of
revascularization, and despite careful analysis of patient
characteristics, there is no way to fully address this issue in
a retrospective, nonrandomized analysis.
However, it is worthwhile remembering that the evidence
favoring first-time CABG in diabetic patients is derived
from a subset analysis of randomized trials and nonrandom-
ized database studies, with only inconsistent results demon-
strated in the latter (described in the previous text). There
has not been a randomized trial comparing revascularization
strategies in patients with previous CABG. Although the
continuing evolution of revascularization techniques has
prompted new trials to compare PCI and CABG (26,27),
these studies were also limited to patients who have not had
prior CABG. Even subset analysis from these trials more
reflective of stenting and other current techniques is not as
helpful in evaluating choices for the high-risk patients
considered in our study. Without randomized data or plans
for a randomized trial in the near future, the value of results
from a large database such as the one analyzed here becomes
that much greater.
Thus, neither the constant evolution of medical and
surgical care nor the observational nature of these data
counters the underlying message. First, compared with
percutaneous intervention, there is significant early hazard
for repeat CABG in diabetic patients. Second, these pa-
tients have significant long-term mortality, and it is the
severity of disease and, perhaps, the profile of multiple risk
factors that best explain this mortality—not a selection of
PCI or CABG. The poor long-term survival of diabetic
patients following revascularization emphasizes the impor-
tance of maximizing medical therapy no matter which
revascularization modality is chosen. This strategy will
include optimization of preventive measures to retard the
progression of atherosclerosis and careful surveillance of
these patients for disease progression.
As far as the fundamental question of whether to proceed
with PCI or redo CABG in diabetic patients after first
coronary surgery, the higher initial mortality of redo CABG
and the similar long-term results seen with either revascu-
larization method argue that for some patients it is appro-
priate to have an initial bias toward PCI, with redo CABG
selected based on individual patient characteristics, such as
the ability to provide new arterial revascularization conduits
or the presence of unprotected native vessel left main
disease. It may also be reasonable to have a bias toward
CABG in class III to IV CHF patients. Nonetheless,
interventional cardiologists and surgeons will often make
Table 4. Multivariate Correlates of Long-Term Mortality (C Index 0.687, Validated 0.684)
Hazard Ratio 95% CI p Value
Age (per 10 years) 1.56 1.42–1.71  0.0001
Male gender 0.83 0.69–1.00 0.045
Ejection fraction (10% increase) 0.77 0.72–0.83  0.0001
Hypertension 1.30 1.09–1.56 0.0032
CHF 0.0030
CHF (if patient has PCI) 1.54 1.25–1.89
CHF (if patient has CABG) 1.19 0.97–1.45
CABG 0.72
CABG (if patient does not have CHF) 1.04 0.84–1.28
CABG (if patient has CHF) 0.80 0.64–1.01
CABG coronary artery bypass graft; CHF congestive heart failure; CI confidence interval; PCI percutaneous coronary
intervention.
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Figure 3. Long-term survival curves for patients with and without New York Heart Association function class III to IV congestive heart failure (CHF) and treated with coronary artery bypass graft surgery
(CABG) or percutaneous coronary intervention (PCI).
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revascularization decisions for these patients based on an-
giographic evaluation specific to each patient, and these
results provide strong support for such decision making.
Evidence that CABG offers better outcome than PCI for a
first revascularization procedure in diabetic patients with
multivessel disease cannot be generalized to diabetic pa-
tients with previous CABG. Rather, choices must be based
on clinical and angiographic evaluation of each patient,
along with patient preference.
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